[Current approaches in the treatment and rehabilitation of patients with neurological diseases after COVID-19. Resolution of the International Experts Forum]. / Lechenie i reabilitatsiya bol'nykh s nevrologicheskimi narusheniyami posle perenesennogo COVID-19. Rezolyutsiya Mezhdunarodnogo foruma ekspertov.

Despite the significant shift in global attention away from the pandemic, the problem of a new coronavirus infection remains important in the medical community. Almost 3 years after the start of the COVID-19 pandemic the issues of rehabilitation and management of delayed manifestations and sequelae of the disease are especially important. According to numerous available data, the new coronavirus infection is characterized by multiorgan lesions. Respiratory dysfunction, clotting disorders, myocardial dysfunction and various arrhythmias, acute coronary syndrome, acute renal failure, GI disorders, hepatocellular damage, hyperglycemia and ketosis, dermatological complications, ophthalmological symptoms and neurological disorders may be found. Significant prevalence of the latter in the post-coronavirus period necessitated this International Expert Forum to develop unified approaches to the management of patients with neurological complications and sequelae of new coronavirus infection based on practical experience and considering the scientific information available on COVID-19. The expert council developed a resolution formulating the tactics for the management of patients with neurological manifestations of COVID-19.

[Effect of antioxidant therapy on neurotrophins and processes of rehabilitation after stroke]. / Vliyanie antioksidantnoi terapii na neirotrofiny i protsessy reabilitatsii posle insul'ta.

The aim of the research was to study the effect of the inclusion in the scheme cytoflavin patient care during the recovery period of ischemic stroke in the neuropsychological changes in the status and content of neurotrophins in serum. For this purpose we surveyed 52 patients who underwent a first ischemic stroke (29 women and 23 men) aged 52-74 years. Patients were divided into 2 groups: primary (25 patients) received in addition to basic therapy cytoflavin: intravenously at 20 ml per 400 ml of 5% glucose solution, 1 time a day for 10 days, then into 2 tablets 2 times a day for half an hour before food for a month, and the comparison group (27 patients) who received standard treatment. The control group consisted of 12 healthy people. In addition to standard clinical and laboratory tests were carried out a comprehensive neuropsychological study and evaluation of the data on the scale NIHSS, Bartell, Beck, Spielberger-Hanin, test «frontal dysfunction of the battery¼ and the Mini-Mental State Examination. Furthermore, determination carried neurotrophic factors: nerve growth factor (NGF) and brain-derived neurotrophic factor brain (BDNF). The study was conducted in the dynamics: before treatment and 2 months after treatment. Patients in the recovery period of the first ischemic stroke revealed moderate manifestations of neuropsychological disorders status and reduction of neurotrophic factors. Inclusion in cytoflavin scheme increased the efficiency of the treatment, which was manifested in a more pronounced when compared with the results of basic therapy, positive dynamics of neurological symptoms and improved cognitive function, accompanied by an increase in BDNF levels. The data on the efficacy and safety allow us to recommend its inclusion in the scheme of treatment of patients in the recovery period after the first carotid ischemic stroke.